astrazeneca plc
(AZN:London Stock Exchange)
astrazeneca plc (AZN) Snapshot
|
Open
3,250 GBp
|
Previous Close
3,240 GBp
|
|
|
Day High
3,271 GBp
|
Day Low
3,241 GBp
|
|
|
52 Week High
05/28/13 - 3,545 GBp
|
52 Week Low
06/18/12 - 2,648 GBp
|
|
|
Market Cap
40.6B
|
Average Volume 10 Days
1.8M
|
|
|
EPS TTM
4.52 GBp
|
Shares Outstanding
1.3B
|
|
|
EX-Date
02/13/13
|
P/E TM
11.2x
|
|
|
Dividend
3.13 GBp
|
Dividend Yield
6.15%
|
astrazeneca plc (AZN) Latest News
astrazeneca plc (AZN) Related Businessweek News
astrazeneca plc (AZN) Details
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a licensing agreement with Ardelyx, Inc. with respect to NHE3 inhibitor program for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD); and a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
astrazeneca plc (AZN) Top Compensated Officers
astrazeneca plc (AZN) Key Developments
AstraZeneca PLC (LSE:AZN) is seeking acquisitions. AstraZeneca is continuing to make acquisitions to boost its developmental drug pipeline to compensate for patent expirations for top-selling products and increased competition from generic drug makers.
AstraZeneca is ending development of a rheumatoid arthritis pill that was one of its few late-stage experimental medicines, following disappointing results. The decision is a fresh blow to AstraZeneca's already sparse new drug pipeline and a bigger setback for Rigel Pharmaceuticals that struck a licensing deal for fostamatinib with Britain's drug maker in 2010. For AstraZeneca, the move will result in a $140 million (£91.5 million) impairment charge relating to intangible assets, to be taken in the second quarter, although this will not affect its financial guidance for 2013, which is based on so-called core earnings. Scrapping fostamatinib is not a complete surprise. However, Briggs Morrison, AstraZeneca's global head of medicines development, said the results of late-stage trials did not measure up to the promising results seen earlier in development.
Bristol-Myers Squibb Company and AstraZeneca PLC announced that the U.S. Food and Drug Administration (FDA) has accepted and granted a Priority Review designation for the Biologics License Application (BLA) for metreleptin, an investigational agent for the treatment of metabolic disorders associated with inherited or acquired lipodystrophy (LD), a rare disease estimated to affect a few thousand people around the world, often with an early age of onset. The FDA grants Priority Review to medicines that may provide a treatment option where little or no adequate therapy exists. Under the Prescription Drug User Fee Act (PDUFA), the FDA aims to complete its review within an eight-month review cycle, rather than the standard 12-month review cycle. The primary data supporting the BLA filing are from the National Institutes of Health (NIH) ongoing, open-label trial in adult and pediatric patients with inherited or acquired LD.
| Recently Viewed | |||
| AZN:LN | 3,246.50 GBp | 0.00 |  |
| Company | Last | Change |
| Abbott Laboratories | $36.89 USD | +0.08 |
| Amgen Inc | $99.08 USD | +1.66 |
| Bristol-Myers Squibb Co | $46.44 USD | -0.36 |
| Eli Lilly & Co | $52.36 USD | +0.31 |
| Novo Nordisk A/S | kr907.00 DKK | 0.00 |
| View Industry Companies | ||
Industry Analysis
AZN
Industry Average
| Valuation | AZN | Industry Range |
| Price/Earnings | 11.2x |
|
| Price/Sales | 2.4x |
|
| Price/Book | 2.9x |
|
| Price/Cash Flow | 11.2x |
|
| TEV/Sales | 2.4x |
|
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
Sponsored Links
To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
